CUSIP 75901B107 · who reports it, how much, and how much it matters to them
19 of the 720 hedge fund managers we track reported shares of REGENXBIO Inc. (Nasdaq: RGNX) on Form 13F for 30 June 2026. Between them they reported USD 116m. The largest position belongs to Redmile Group, at USD 52m. The manager with the most riding on it is 22NW, where it is 5.6% of the reported book.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Redmile Group10 funds on PPLI.com | USD 52m | 3.5% |
| 2 | Marshall Wace LLP84 funds on PPLI.com | USD 15m | 0.0% |
| 3 | D. E. Shaw & Co.15 funds on PPLI.com | USD 8.5m | 0.0% |
| 4 | Two Sigma Investments35 funds on PPLI.com | USD 8m | 0.0% |
| 5 | Citadel Advisors32 funds on PPLI.com | USD 8m | 0.0% |
| 6 | 22NW1 fund on PPLI.com | USD 5.9m | 5.6% |
| 7 | Millennium Management6 funds on PPLI.com | USD 5.8m | 0.0% |
| 8 | Renaissance Technologies13 funds on PPLI.com | USD 3.1m | 0.0% |
| 9 | Hudson Bay Capital Management8 funds on PPLI.com | USD 2.7m | 0.0% |
| 10 | Walleye Capital8 funds on PPLI.com | USD 2.4m | 0.0% |
| 11 | Balyasny Asset Management25 funds on PPLI.com | USD 887,000 | 0.0% |
| 12 | Aquatic Capital Management3 funds on PPLI.com | USD 527,000 | 0.0% |
| 13 | Voleon Capital Management13 funds on PPLI.com | USD 486,000 | 0.0% |
| 14 | Engineers Gate Manager1 fund on PPLI.com | USD 412,000 | 0.0% |
| 15 | Brevan Howard Capital Management39 funds on PPLI.com | USD 397,000 | 0.0% |
| 16 | Lion Point Capital1 fund on PPLI.com | USD 319,000 | 1.5% |
| 17 | Tudor Investment Corporation10 funds on PPLI.com | USD 286,000 | 0.0% |
| 18 | Boxer Capital Management1 fund on PPLI.com | USD 180,000 | 0.0% |
| 19 | The Quarry1 fund on PPLI.com | USD 1,965 | 0.0% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | 22NW | USD 5.9m | 5.6% |
| 2 | Redmile Group | USD 52m | 3.5% |
| 3 | Lion Point Capital | USD 319,000 | 1.5% |
| 4 | Aquatic Capital Management | USD 527,000 | 0.0% |
| 5 | Boxer Capital Management | USD 180,000 | 0.0% |
| 6 | Marshall Wace LLP | USD 15m | 0.0% |
| 7 | Walleye Capital | USD 2.4m | 0.0% |
| 8 | Voleon Capital Management | USD 486,000 | 0.0% |
| 9 | Hudson Bay Capital Management | USD 2.7m | 0.0% |
| 10 | Two Sigma Investments | USD 8m | 0.0% |
REGENXBIO Inc. trades under the symbol RGNX on the Nasdaq. Its CUSIP, the code used on Form 13F, is 75901B107.
19 of the 720 hedge fund managers PPLI.com tracks reported REGENXBIO Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by Redmile Group (USD 52m), Marshall Wace LLP (USD 15m), D. E. Shaw & Co. (USD 8.5m), Two Sigma Investments (USD 8m) and Citadel Advisors (USD 8m).
19 managers in our coverage reported it, and between them they run 306 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
22NW, where the position was 5.6% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with REGENXBIO Inc. or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.